{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-173983","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.446461+00:00","generated_at":"2026-05-17T19:34:33.883467+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viridian reports cash of $563.4M; BLA for veligrotug on track for 2H 2025","bullets":["Cash, cash equivalents and short-term investments $563.4M as of June 30, 2025, down from $636.6M at March 31, 2025; runway into 2H 2027.","R&D expenses $86.6M in Q2 2025 (up from $56.2M in Q2 2024) driven by more clinical trials and higher headcount.","Veligrotug BLA submission on track for 2H 2025; U.S. commercial launch anticipated in 2026 if approved.","Exclusive license with Kissei for Japan: $70M upfront, up to $315M in milestones, plus tiered royalties.","Veligrotug durability data: 70% of proptosis responders at week 15 maintained response at week 52."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-173983","json":"https://secwatch.observer/filing/0001193125-25-173983.json","markdown":"https://secwatch.observer/filing/0001193125-25-173983.md","text":"https://secwatch.observer/filing/0001193125-25-173983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/0001193125-25-173983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/d20477d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:34:33.883467+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}